Stanford University researchers working on a project supported by a U.S. National Science Foundation grant have determined the structure of a large signalling protein in response to infection, inflammation and immune cell generation.
The system reveals how the protein Janus kinase, or JAK, transmits signals sent by immune cell growth factors called cytokines.
When the structure of the signalling protein changes because of genetic mutations, it can indicate the emergence of blood cancers known as myeloproliferative neoplasms. The team published the results of the work in Science. The research could impact the development of drugs to treat myeloproliferative neoplasms, especially those that target proteins that allow cancer to develop.
Scientists find mutated protein structures in blood cancers; here, myeloma cells produce monoclonal proteins. Image credit: scientificanimations.com via Wikimedia Commons, CC-BY-SA-4.0
“The question of how JAKs transmit the cytokine signal has been a huge missing link in our understanding of cell signalling,” said corresponding author Christopher Garcia. “The structure also tells us how the mutant JAK works and how it leads to blood cancers. Our model of JAK structure gives us an atomic blueprint for how one could make mutant-selective medicines to treat these cancers.”
When JAKs are brought close together, they activate one another. According to the scientists, that's the complex that gets the signalling engine running. The constant signals lead to unabated cell proliferation.
The findings could result in treatments that don't affect normal proteins and have less toxic side effects. The team is working to develop drugs to target other mutations involved in cytokine signalling.
Source: NSF